Safety of live-attenuated influenza vaccination in cystic fibrosis

Pediatrics

Volumn 134, Issue 4, 2014, Pages e983-e991

  Boikos, Constantina ^a   De Serres, Gaston ^b,c   Lands, Larry C ^d   Boucher, François D ^e   Tapiéro, Bruce ^f   Daigneault, F Patrick ^g   Quach, Caroline ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^d MONTREAL CHILDREN S HOSPITAL   (Canada)

^e LAVAL UNIVERSITY   (Canada)

^f UNIVERSITY OF MONTREAL   (Canada)

^g RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Childhood vaccination; Cystic fibrosis; Influenza; Live attenuated influenza virus vaccine; Vaccine; Vaccine safety

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; INFLUENZA VACCINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTHRALGIA; ARTICLE; ASTHMA; CANADA; CHILD; CHILL; CLINICAL TRIAL; COMORBIDITY; COUGHING; CYSTIC FIBROSIS; DIARRHEA; DISEASE DURATION; DRUG SAFETY; DRUG USE; DYSPHAGIA; DYSPNEA; EYE REDNESS; FACIAL SWELLING; FATIGUE; FEMALE; FEVER; FOLLOW UP; GROUPS BY AGE; HEADACHE; HOSPITALIZATION; HUMAN; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; MYALGIA; NAUSEA; NOSE OBSTRUCTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT DISEASE; RHINORRHEA; RISK BENEFIT ANALYSIS; RISK REDUCTION; SLEEP DISORDER; SORE THROAT; SWELLING; VOMITING; WHEEZING; ADVERSE EFFECTS; CHEMICALLY INDUCED; COHORT ANALYSIS; INFLUENZA, HUMAN; INTRANASAL DRUG ADMINISTRATION; RESPIRATORY SOUNDS; VACCINATION;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ARTHRALGIA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYSTIC FIBROSIS; FATIGUE; FEMALE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; PROSPECTIVE STUDIES; RESPIRATORY SOUNDS; VACCINATION;

EID: 84918576245     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-0887     Document Type: Article

References (32)

1. Dupuis A, Hamilton D, Cole DE, Corey M. Cystic fibrosis birth rates in Canada: a decreasing trend since the onset of genetic testing. J Pediatr. 2005;147(3):312-315
2. Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med. 1995;152 (6 pt 1):2111-2118 MuhlebachM.S. StewartP.W. LeighM.W. NoahT.L.Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patientsAm J Respir Crit Care Med19991601186-191Muhlebach MS, Stewart PW, Leigh MW, Noah TL. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med. 1999;160(1):186-191
3. Muhlebach MS, Reed W, Noah TL. Quantitative cytokine gene expression in CF airway. Pediatr Pulmonol. 2004;37(5):393-399
4. Kube D, Sontich U, Fletcher D, Davis PB. Proinflammatory cytokine responses to P. aeruginosa infection in human airway epithelial cell lines. Am J Physiol Lung Cell Mol Physiol. 2001;280(3):L493-L502
5. McKeon DJ, Condliffe AM, Cowburn AS, et al. Prolonged survival of neutrophils from patients with Delta F508 CFTR mutations. Thorax. 2008;63(7):660-661
6. Wat D, Gelder C, Hibbitts S, et al. The role of respiratory viruses in cystic fibrosis. J Cyst Fibros. 2008;7(4):320-328
7. Conway SP, Simmonds EJ, Littlewood JM. Acute severe deterioration in cystic fibrosis associated with influenza A virus infection. Thorax. 1992;47(2):112-114
8. Ferson MJ, Morton JR, Robertson PW. Impact of influenza on morbidity in children with cystic fibrosis. J Paediatr Child Health. 1991;27(5):308-311
9. Smyth AR, Smyth RL, Tong CY, Hart CA, Heaf DP. Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis. Arch Dis Child. 1995;73(2):117-120
10. van Ewijk BE, van der Zalm MM, Wolfs TF, et al. Prevalence and impact of respiratory viral infections in young children with cystic fibrosis: prospective cohort study. Pediatrics. 2008;122(6):1171-1176
11. Renk H, Regamey N, Hartl D. Influenza A (H1N1)pdm09 and cystic fibrosis lung disease: a systematic meta-analysis. PLoS ONE. 2014;9(1):e78583
12. National Advisory Committee on Immunization. Recommendations on the use of live, attenuated influenza vaccine (FluMist)-Supplemental Statement on Seasonal Influenza Vaccine for 2011-2012. Canada Communicable Disease Report (vol. 37, ACS-7). November 2011
13. National Advisory Committee on Immunization (NACI). Statement on Seasonal Influenza Vaccine for 2011-2012. In Canada Communicable Disease Report (vol. 37, ACS-5). October 2011
14. Belshe RB, Edwards KM, Vesikari T, et al; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356(7):685-696
15. Protocole d'immunisation du Québec. 2013. Available at: http://publications.msss.gouv.qc. ca/acrobat/f/documentation/piq/piq-complet. pdf. Accessed on March 15, 2014.
16. Mayer-Hamblett N, Saiman L, Lands LC, et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemp Clin Trials. 2013;36(1):99-105
17. Cates CJ, Jefferson TO, Rowe BH. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev. 2008; (2):CD000364
18. Dharmaraj P, Smyth RL. Vaccines for preventing influenza in people with cystic fibrosis. Cochrane Database Syst Rev. 2009; (4):CD001753
19. Report of Adverse Events Following Immunization. 2013. Available at: www.phac-aspc. gc.ca/im/aefi-essi-form-desc-eng.php. Accessed on March 15, 2014.
20. Xu SGP, Mullooly J, McClure D, Hambidge SJ, Glanz J. Fitting parametric and semiparametric conditional poisson regression models with Cox's partial likelihood in selfcontrolled case series and matched cohort studies. J Data Sci. 2010;8(2010):349-360
21. Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med. 2006;25(10):1768-1797
22. The 2011 Annual Canadian Cystic Fibrosis Registry. Toronto, Canada: Cystic Fibrosis Canada; 2011
23. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis. 2003;37(suppl 3): S225-264
24. Schaad UB, Bühlmann U, Burger R, et al. Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis. Antimicrob Agents Chemother. 2000;44(5): 1163-1167
25. Izurieta HS, Haber P, Wise RP, et al. Adverse events reported following live, coldadapted, intranasal influenza vaccine. JAMA. 2005;294(21):2720-2725
26. Gaglani MJ, Piedra PA, Riggs M, Herschler G, Fewlass C, Glezen WP. Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. Pediatr Infect Dis J. 2008;27(5):444-452
27. Skowronski DM, Strauss B, De Serres G, et al. Oculo-respiratory syndrome: a new influenza vaccine-associated adverse event? Clin Infect Dis. 2003;36(6):705-713
28. Skowronski DM, Jacobsen K, Daigneault J, et al. Solicited adverse events after influenza immunization among infants, toddlers, and their household contacts. Pediatrics. 2006;117(6):1963-1971
29. Wilson K, Hawken S, Kwong JC, et al. Adverse events following 12 and 18 month vaccinations: a population-based, selfcontrolled case series analysis. PLoS ONE. 2011;6(12):e27897
30. Weldeselassie YG, Whitaker HJ, Farrington CP. Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice. Epidemiol Infect. 2011;139(12):1805-1817
31. Maclure M, Fireman B, Nelson JC, et al. When should case-only designs be used for safety monitoring of medical products? Pharmacoepidemiol Drug Saf. 2012;21 (suppl 1):50-61
32. Zeng C, Newcomer SR, Glanz JM, et al. Bias correction of risk estimates in vaccine safety studies with rare adverse events using a self-controlled case series design. Am J Epidemiol. 2013;178(12): 1750-1759